



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

UD

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/895,435	06/30/2001	A. Francis Stewart	9882-012	8975
7590	09/22/2004		EXAMINER	
Craig J. Arnold, Esq. AMSTER, ROTHSTEIN & EBENSTEIN LLP 90 Park Avenue New York, NY 10016			MCGARRY, SEAN	
		ART UNIT	PAPER NUMBER	
		1635		

DATE MAILED: 09/22/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/895,435	STEWART ET AL.	
	Examiner	Art Unit	
	Sean R McGarry	1635	.

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 09 June 2004.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-5,11-20 and 53-74 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-5,11-20,53-55,57-60,62-65 and 67-74 is/are rejected.
- 7) Claim(s) 56,61 and 66 is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: sequence alignment.

DETAILED ACTION

Claims 1-5, 11-20, 53-55, 57-60, 62-65, and 67-74 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The amendment filed 6/8/04 introduces new matter into the disclosure. The added material which is not supported by the original disclosure is as follows: The language introduced into the claims refers to functional variants that alter SEQ ID NO: 3 only in the central crossover region and also refers to inverted repeat alterations at this location. Applicant has pointed to page 5 of the specification. It is noted that nowhere on page 5 is there a reference to crossover region modifications or inverse repeat modifications in the context of the claimed invention.

Applicant is required to cancel the new matter in the reply to this Office Action.

Claims 1-5, 11-13, 15-20, 54, 55, 57, 59, 60, 64, 65, and 67 remain and new claims 68-74 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably

convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.

The specification discloses SEQ ID NO:3 which corresponds to the cDNA/genomic DNA encoding the human/rat/mouse species of TRT promoter and SEQ ID NO: 2 which corresponds to TRT'. SEQ ID NO: 3 and SEQ ID NO: 2 meet the written description provisions of 35 USC 112, first paragraph. However, the claims are directed to encompass "functional variants thereof" which may correspond to sequences from other species, mutated sequences, allelic variants, splice variants, sequences that have a recited degree of identity (similarity, homology), functional variants that are altered from SEQ ID NO: 3 only in the crossover region including, but not limited to inverted repeat, and so forth. None of these sequences meet the written description provision of 35 USC 112, first paragraph. The specification provides insufficient written description to support the genus encompassed by the claim. It is noted that applicant's specification provides a description of what might be a "functional variant" at pages 6 and 11, for example. Applicant description/definition requires only that at least some change in sequence is made. There is no upper limit to the changes and the functional variants read on species with no apparent structural similarity as SEQ ID NO: 2 or 3 but which would have the same function. It is noted that the specification provides a few examples, but only examples where the structure is quite similar to that of SEQ ID NO:2 or 3 for example. The specification provides a method to screen for

functional variants. The specification provides potential methods for finding species of the claimed invention , but fails to provide the structure of these species.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

With the exception of SEQ ID NO: 3 or 2, the skilled artisan cannot envision the detailed chemical structure of the encompassed polynucleotides, **regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The nucleic acid itself is required.** See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. V. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. In Fiddes v. Baird, 30 USPQ2d 1481, 1483, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

Finally, University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404, 1405 held that:

...To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can

clearly conclude that "the inventor invented the claimed invention." *Lockwood v. American Airlines, Inc.* , 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); *In re Gosteli* , 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) ("[T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." *Lockwood*, 107 F.3d at 1572, 41 USPQ2d at 1966.

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the '525 patent, "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. *Fiers v. Revel* , 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, "an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself." *Id.* at 1170, 25 USPQ2d at 1606.

The name cDNA is not itself a written description of that DNA; it conveys no distinguishing information concerning its identity. While the example provides a

process for obtaining human insulin-encoding cDNA, there is no further information in the patent pertaining to that cDNA's relevant structural or physical characteristics; in other words, it thus does not describe human insulin cDNA.

Describing a method of preparing a cDNA or even describing the protein that the cDNA encodes, as the example does, does not necessarily describe the cDNA itself. No sequence information indicating which nucleotides constitute human cDNA appears in the patent, as appears for rat cDNA in Example 5 of the patent. Accordingly, the specification does not provide a written description of the invention of claim 5.

Therefore, only SEQ ID NO: 3 or 2 but not the full breadth of the claim (or none of the sequences encompassed by the claim) meets the written description provision of 35 USC 112, first paragraph. The species specifically disclosed are not representative of the genus because the genus is highly variant. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.)

Applicants arguments filed 6/08/04 have been considered but are not persuasive.

Applicant argues that the invention is now limited to functional variants where the variants differ from SEQ ID NO: 3 only in the crossover region. Applicant asserts that such functional variants are within the scope of the invention and that such variants are sufficiently described at page 5 of the specification. It is noted that there is no disclosure of a central crossover region in the context of the claimed invention on page 5. There

are no functional variants disclosed that posses the requisite function of the exemplified nucleic acids. The declaration of Bernard Hallet does not take the place of an adequate description of the invention in the specification. It is again noted that **regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The nucleic acid itself is required.** See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993). Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.) So, although the declaration might provide evidence of enablement for a particular embodiment, it does not remedy the lack of an adequate written description of the invention.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, 11-13, 53, 55, 58, 60 remain rejected under 35 U.S.C. 102(b) as being anticipated by Mahillon et al [NAR Vol. 16(24):1988].

Mahillon et al disclose a pGI2 plasmid sequence (a vector with sequences other than Tn4430 (ie “heterologous” as defined in the instant specification at page 6, for example)). The sequence includes SEQ ID NO:3 and SEQ ID NO:2 and does not

contain more than 200 contiguous nucleotides of SEQ ID NO: 4. The pGI2 plasmid was cloned and characterized in E.coli cells.

Claims 1-3, 11-13, 53, 55, 58, and 60 remain under 35 U.S.C. 102(b) as being anticipated by Mahillon et al [The EMBO Journal Vol. 7(5):1515-1526, 1988].

Mahillon et al have disclosed several plasmid vectors that comprises SEQ ID NO: 3 and SEQ ID NO: 2 while not comprising more 100 contiguous nucleotides of SEQ ID NO: 4. Mahillon et al have disclosed that the plasmid vectors have various selectable markers which of themselves would be "heterologous" nucleic acid sequences as defined in the instant specification (see page 6, for example).

Claims 20, 63, and 65 remain rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Mahillon et al [The EMBO Journal Vol. 7(5):1515-1526, 1988].

Mahillon et al is relied upon as above. Additionally Mahillon et al disclose that the vectors described encode Tnpl and further the plasmids are in E. coli cells which are capable of expressing such heterologous proteins from vectors. Although not specifically disclosed in the reference it would appear inherent in the reference that the disclosed compositions/compounds in [a] container/s since one would keep such compositions in a container to keep the experimental compounds free from contamination, to minimize loss due to evaporation, or to keep them [the experimental

compounds] from covering a work area, for example. If the compositions/compounds disclosed in the reference were not in containers it would have been obvious to do so for the same reasons above where inherency has been presumed.

Applicants arguments filed 6/08/04 have been considered but are not persuasive.

Applicant argues that the prior art contains all 249 nucleotides of SEQ ID NO: 4 and provides sequences as evidence. These sequences are not convincing since these sequences are not those sequences of the prior art applicant is provided as an attachment to this Official Action an alignment of the prior art reference and SEQ ID NO: 4 of the instant application. It is clear that neither sequence contains more than 200 contiguous nucleotides of SEQ ID NO: 4. Applicant argues that one would not provide the possible constituents of the claimed kits in separate containers. It is noted that the rejection of record clearly set forth the reasons for storage in a container or containers. Applicant argues as if the only other possible constituent is a Tnpl protein. This is not the case since the invention also considers a cell capable of expressing a Tnpl protein, for example.

Claims 56, 61, and 66 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean R McGarry whose telephone number is (571) 272-0761. The examiner can normally be reached on M-Th (6:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (571) 272-0760. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Sean R McGarry
Primary Examiner
Art Unit 1635

SRM

1635

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model.

Run on: February 28, 2004, 05:52:06 ; Search time 1253.82 Seconds
(without alignments)
8607.626 Million cell, updates/sec.

SEQ ID NO: 4

Title: US-09-895-435A-4

Perfect score: 249

Sequence: 1 ggggttacccggccatctcg.....gacggggggaaatccatcg 249

Scoring table: IDENTITY_NUC

Gapopen 10.0 , Gapext 1.0

Searched: 3470272 seqs, 2167151695 residues

Total number of hits satisfying chosen parameters: 6940544

Post-processing: Minimum Match 0%

Maximum DB seq length: 0

Maximum DB seq length: 2000000000

Minimum Match %: 0

Maximum Match %: 100%

Listing first 45 summaries

Database : GenProb1:

1: gb_ba:*

2: gb_htg:*

3: gb_in:*

4: gb_cm:*

5: gb_ov:*

6: gb_pat:*

7: gb_ph:*

8: gb_pl:*

9: gb_pr:*

10: gb_rn:*

11: gb_sb:*

12: gb_sv:*

13: gb_uu:*

14: gb_vl:*

15: em_ba:*

16: em_fan:*

17: em_hum:*

18: em_in:*

19: em_mu:*

20: em_om:*

21: em_or:*

22: em_ov:*

23: em_pat:*

24: em_ph:*

25: em_pi:*

26: em_rn:*

27: em_sc:*

28: em_un:*

29: em_vl:*

30: em_hdg_hum:*

31: em_hdg_other:*

32: em_hdg_mus:*

33: em_hdg_pin:*

35: em_hdg_rod:*

36: em_hdg_man:*

37: em_hdg_vrt:*

38: em_sv:*

39: em_hdg_hum:*

40: em_hdg_mus:*

41: em_hdg_other:*

Database : GenProb1:

1: gb_ba:*

2: gb_htg:*

3: gb_in:*

4: gb_cm:*

5: gb_ov:*

6: gb_pat:*

7: gb_ph:*

8: gb_pl:*

9: gb_pr:*

10: gb_rn:*

11: gb_sb:*

12: gb_sv:*

13: gb_uu:*

14: gb_vl:*

15: em_ba:*

16: em_fan:*

17: em_hum:*

18: em_in:*

19: em_mu:*

20: em_om:*

21: em_or:*

22: em_ov:*

23: em_pat:*

24: em_ph:*

25: em_pi:*

26: em_rn:*

27: em_sc:*

28: em_un:*

29: em_vl:*

30: em_hdg_hum:*

31: em_hdg_other:*

32: em_hdg_mus:*

33: em_hdg_pin:*

35: em_hdg_rod:*

36: em_hdg_man:*

37: em_hdg_vrt:*

38: em_sv:*

39: em_hdg_hum:*

40: em_hdg_mus:*

41: em_hdg_other:*

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	249	100.0	249	6 AX671525	AX671525 Sequence
2	244	98.0	244	6 AX671522	AX671522 Sequence
3	241	96.8	4149	1 BTM4430	X07651 Bacillus th
4	241	96.8	9672	1 BTPG12XX	X12481 Bacillus th
5	118	47.4	118	6 AX671523	AX671523 Sequence
6	114	45.9	116	6 AX671528	AX671528 Sequence
7	114	45.9	116	6 AX671529	AX671529 Sequence
8	53	21.3	20150	1 AB04263	Diplomonadidae
9	53	21.3	20150	1 AB04263	Diplomonadidae
10	53	21.3	15548	3 PFMAU3P2	AL034588 Plasmid
11	53	21.3	20429	3 AC00506	Plasmid
12	53	21.3	253132	3 AE014846	ABD04846
13	52.8	21.2	609	8 PR0251061	AC151061 Plasmodia
14	52	20.9	1018	8 AP40569	AC1569 Clavijia s
15	51.8	20.8	2150	3 AC11683	AC11683 Dictyostelium
16	51.8	20.8	83332	9 AC095051	Homo sapi
17	51.8	20.8	34050	3 PFA939353	AL929353 Plasmid
18	51.4	20.6	27156	3 LE01443	AE01443
19	51.2	20.6	61869	2 AC10381	Homo sapi
20	51	20.5	124	6 AX671531	AX671531 Sequence
21	51	20.5	60529	2 AC14825	Danio rer
22	51	20.5	60985	2 AC05651	Arabidopsis
23	51	20.5	254632	3 AE014818	AE014818 Plasmid
24	50.8	20.4	203958	5 AL954339	Zebrafish
25	50.4	20.2	11000	2 PMAL13_22	Continuum (23 o
26	50.2	20.2	6550	6 AX34952	Sequence
27	50.2	20.2	93858	9 HSUJ105949	AL116524 Human DNA
28	50.2	20.2	10942	2 AC091859	AC0101859 Homo sapi
29	50.2	20.2	11372	9 AL161613	Continuum (2 of
30	50.2	20.2	11372	9 AL161613	AL161613 Human DNA
31	50.2	20.2	14263	9 AC091988	AC01188 Homo sapi
32	50.2	20.2	17043	9 AC027197	AC027197 Homo sapi
33	50.2	20.2	171181	9 BX005037	BX005037 Human DNA
34	50.2	20.2	183366	9 AL591926 Human DNA	AL162731 Human DNA
35	50.2	20.2	188062	9 AL162731	AB014820 Plasmid
36	50.2	20.2	250029	3 AE014820	AE014820 Plasmid
37	50.2	20.2	250107	3 AE014848	AE014848 Plasmid
38	50.2	20.2	340552	3 PFA939354	AL929354 Plasmid
39	50	20.1	11308	1 AE007654	AE007654 Clostridi
40	50	20.1	163316	9 AL16420 Human DNA	AL16420 Human DNA
41	50	20.1	18083	2 BX533038	BX533038 Human DNA
42	49.8	20.0	32392	6 AX39737	AX39737 Sequence
43	49.8	20.0	50000	6 AX39733	AX39733 Sequence
44	49.8	20.0	23392	14 AF250284	AF250284 Amoeba m
45	49.8	20.0	23392	14 AF250284	AF250284 Amoeba m

ALIGNMENTS

RESULT 1	LOCUS	DEFINITION	ACCESSION	VERIFICATION	KEYWORDS	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL
	AX671525	Sequence 4 from Patent WO03004652	AX671525	GI:29329875			PAT 27-MAR-2003	Stewart, P.A., Zhang, Y. and Hallett, B.	Use of a tyrosine recombinase for genetic engineering	Patent: WO 03004652-A 4 16-JAN-2003;

Pred. No. is the number of results predicted by chance to have a

The European Molecular Biology Laboratory (DE) ; L'Université Catholique De Louvain (BE)
 Location/Qualifiers
 1. 249 /organism="Bacillus thuringiensis"
 /mol_type="assigned DNA"
 /db_Xref="taxon:1428"

ORIGIN

Query Match Similarity 100.0% Score 249; DB 6; Length 249;
 Best Local Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGTACGCCAGATTGAAAARAC CAGCTTAAAGAATCAGTTAAACAG 60
 Db 61 AATAATTCATTATCCGTGACCATACATGTTCTTTTATACACATG 60
 Qy 61 AATAATTCATTATCCGTGACCATACATGTTCTTTTATACACATG 60
 Db 61 AATAATTCATTATCCGTGACCATACATGTTCTTTTATACACATG 60
 Qy 121 CCAATAATTAATTTGGTTTATAGGGTTTAACTACGC 180
 Db 121 CCAATAATTAATTTGGTTTATAGGGTTTAACTACGC 180
 Qy 181 AACACATTATTCGATAATAATTTAGCCGACAAATTATAGCCGAGGA 240
 Db 181 AACACATTATTCGATAATAATTTAGCCGACAAATTATAGCCGAGGA 240
 Qy 241 AATCACATG 249
 Db 241 AATCACATG 249

RESULT 2
 AX671522 LOCUS AX671522 244 bp DNA linear PAT 27-MAR-2003
 DEFINITION Sequence 1 from Patent WO03004652.
 ACCESSION AX671522_1 GI:29229872
 VERSION 1
 KEYWORDS
 SOURCE Bacillus thuringiensis
 ORGANISM Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus cereus Group.

REFERENCE 1 Stewart, P. A., Zhang, Y. and Waller, B.
 AUTHORS Use of a tyrosine recombinase for genetic engineering
 TITLE Patent: WO 03004652-A 1 16 JAN 2003;
 JOURNAL The European Molecular Biology Laboratory (DE) ; L'Université Catholique De Louvain (BE)
 Location/Qualifiers 1. 244 /organism="Bacillus thuringiensis"
 /mol_type="assigned DNA"
 /db_Xref="taxon:1428"

ORIGIN

Query Match Similarity 98.0% Score 244; DB 6; Length 244;
 Best Local Matches 244; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GGTAACGCCAGATTGGA AAAACCAAGCTTAAGAAATCAGTTAAATCAA 62
 Db 1 GGTAACGCCAGATTGGA AAAACCAAGCTTAAGAAATCAGTTAAATCAA 60
 Qy 63 AATAATTCATTATCCGTGACCATACATGTTCTTTTATACAC 122
 Db 61 AATAATTCATTATCCGTGACCATACATGTTCTTTTATACAC 120
 Qy 123 CAATTAATTTGTTGTTGTTAGGGTTATAATAATAATCTAGGGTTAACCAA 182
 Db 121 CAATTAATTTGTTGTTGTTAGGGTTATAATAATAATCTAGGGTTAACCAA 180

RESULT 3
 BTM4430 LOCUS BTM4430 4149 bp DNA transposon Tr4430.
 DEFINITION Xc07651.1 GI:40347
 VERSION X07651.1
 KEYWORDS Plasmid; resolvase; trpA gene; trpI gene; transposase; transposon.
 SOURCE
 ORGANISM Bacillus thuringiensis
 Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus; Bacillus cereus group.
 REFERENCE 1 (bases 1 to 4149)
 Authors Nahilou, J. and Lereclus, D.
 Title Structural and functional analysis of Tr4430: identification of an integrase-like protein involved in the co-integrate-resolution process.
 JOURNAL EMBO J. 7 (5), 1515-1526 (1988)
 MEDLINE 98312602
 FORMED Data kindly reviewed (03-APR-1989) by Lereclus, D.
 COMMENT Location/Qualifiers 1. 4149
 FEATURES /organism="Bacillus thuringiensis"
 /mol_type="Genomic DNA"
 /strain="H1.1"
 /db_xref="taxon:1428"
 /map="Plasmid PG12"
 /clone="PG120"
 /clone_1_id="PBR322"
 /repeat_unit 1..38
 /note="inverted repeat A"
 CDS 247..1101
 /note="unnamed protein product; put. resolvase Trp I (AA 1 - 2842151
 /codon_start=1
 /transl_table=11
 /protein_id="CAA10491.1"
 /db_xref="GO:14038"
 /db_xref="PI:0020"
 /db_xref="SWISS-PROT:P100030"
 /translation="MDYAKQSSYIJKQENTENTVQGTISIRQYIKWFGESYDKELT
 KLYKRONILYIYSTLQYDMLAKSLNKHKSISLAKPNEQDQVLSKNDENIVK
 QTVYASPTQIVLENDKKEFLQSVTEEDNNKNTYATLLAYTQVLSKNDENIVQ
 TGCCTIRSGGGGTIVLNLKSVLSKVLSAIKYLDKTSIAHSPEFISCKRENDRT
 LVNRIFPKSYTNTVTPHQURHPPCTRAIEKFSTIEVANQAGNSHTTLLYNPLQL
 LKRNKELL"
 CDS 1120..4083
 /note="unnamed protein product; transposase Trp A (AA 1 - 987)"
 /codon_start=1
 /transl_table=11
 /protein_id="CAA10492.1"
 /db_xref="GO:14039"
 /db_xref="SWISS-PROT:P10021"
 /translation="MKGKLISBAGCNELMDLSLTEDDLVTFTRFSKHDHLILKHR
 RGYNRUGPAIRLVLRPGWSITBYCDIPOQWVYVTERLRPPBESLYAVGRGTLW
 ENGLGPRTEVYQKQNSSEPKYKELQGJUQAMDNNTLYIETTSRCKVLPAM
 YVDEDTWQADQKVTSLQDQVLSKVLQDQDALLFTGTSPLKWDKVAQF
 SPESPFLKVIDRLOFQKIGLTTINTNTRQARLGSKCQDOLQNGKLNKEKQFIVTCG
 LVSEFLLEITODLIDYAISHDLMQNLCTKGKQDOLQNGKLNKEKQFIVTCG
 TLEIEKETGSDAFALDVSMSNNKVEOSPEAKLRSRPNYLYDILNNTYSYVRYA
 PTLLRSLHFRATKSGEPFLQADTILNETGKVKPHGAPLHPSNRWQHVTDDG

NINHRYELALTEHRNHRSGDIPSSRSRERAFDDLIPYDEMEVSINPNGLTJ LKABDITDRINLNEHLWLSKNSKSECEGVDISOKGHVBLDRPEAKAFKL HSMPLRIKLTDLLEVASNTGFDQFATGSTSPODEQNVYLATMAGTCNGTKL MAEAPGJSTROMANASOKRMYDAMYVAOSLUNPKOECOKLSSYMGDTISSSGCM LSIAVRSLHADSNPHGKGKGTIYRSQSAYAHTVKNITNDAHLJLJHE TDLWDYLSKHAVERRVRVQGLNGEATLACCTTGTGCGTAACTGGTAACTGG KGKINVLYKIKENYDILRFLYASOTGKYSQSSALMIGKLGSYARQNDQGMRASLN TFLWDYLSKHAVERRVRVQGLNGEATLACCTTGTGCGTAACTGGTAACTGG ILLNLSVWNTVNEKAWEELKARGEFFEDLMPYAWPFGWBNFHFLGEYKPEGLHTD QMLNLRLPRKEPPFS"																																																																				
4112 . 4149 /note= "inverted repeat A'"																																																																				
repeat_unit																																																																				
GIN																																																																				
<table border="1"> <thead> <tr> <th>query</th> <th>Match</th> <th>Score</th> <th>Length</th> </tr> </thead> <tbody> <tr> <td>96.8%</td> <td>DB 1;</td> <td>4149;</td> <td></td> </tr> <tr> <td>98.0%</td> <td>Pred. No.</td> <td>1.4e-31;</td> <td></td> </tr> <tr> <td>244; Conservative</td> <td>0;</td> <td>Mismatches</td> <td>0;</td> </tr> <tr> <td></td> <td>5;</td> <td>Indels</td> <td>0;</td> </tr> <tr> <td></td> <td></td> <td>Gaps</td> <td>0;</td> </tr> <tr> <td>1 GGGGTACGCCAGATTCTGGAAAAACCGCTAGAAAATCAGAGTAAATAATCG 60</td> <td></td> <td></td> <td></td> </tr> <tr> <td>1 GGGGTACGCCAGATTCTGGAAAAACCGCTAGAAAATCAGAGTAAATAATCG 60</td> <td></td> <td></td> <td></td> </tr> <tr> <td>61 AAATATATCAATTCTTGACACATACTACAGTGTCTTTTAACTATACAA 120</td> <td></td> <td></td> <td></td> </tr> <tr> <td>61 AAATATATCAATTCTTGACACATACTACAGTGTCTTTTAACTATACAA 120</td> <td></td> <td></td> <td></td> </tr> <tr> <td>121 CACAAATAATTGTTGTTGATTAGGTGTTATAATAATAACTCTAGGGTTAACGC 180</td> <td></td> <td></td> <td></td> </tr> <tr> <td>121 CACAAATAATTGTTGTTGATTAGGTGTTATAATAATAACTCTAGGGTTAACGC 180</td> <td></td> <td></td> <td></td> </tr> <tr> <td>181 AACACATTATGGAATTAATACCTTGTAGCCACATTATAGACGGGAGGA 240</td> <td></td> <td></td> <td></td> </tr> <tr> <td>181 AACACATTATGGAATTAATACCTTGTAGCCACATTATAGACGGGAGGA 240</td> <td></td> <td></td> <td></td> </tr> <tr> <td>241 AATCACACG 249</td> <td></td> <td></td> <td></td> </tr> <tr> <td>241 AATCACACG 249</td> <td></td> <td></td> <td></td> </tr> <tr> <td>241 AATCACATG 249</td> <td></td> <td></td> <td></td> </tr> </tbody> </table>	query	Match	Score	Length	96.8%	DB 1;	4149;		98.0%	Pred. No.	1.4e-31;		244; Conservative	0;	Mismatches	0;		5;	Indels	0;			Gaps	0;	1 GGGGTACGCCAGATTCTGGAAAAACCGCTAGAAAATCAGAGTAAATAATCG 60				1 GGGGTACGCCAGATTCTGGAAAAACCGCTAGAAAATCAGAGTAAATAATCG 60				61 AAATATATCAATTCTTGACACATACTACAGTGTCTTTTAACTATACAA 120				61 AAATATATCAATTCTTGACACATACTACAGTGTCTTTTAACTATACAA 120				121 CACAAATAATTGTTGTTGATTAGGTGTTATAATAATAACTCTAGGGTTAACGC 180				121 CACAAATAATTGTTGTTGATTAGGTGTTATAATAATAACTCTAGGGTTAACGC 180				181 AACACATTATGGAATTAATACCTTGTAGCCACATTATAGACGGGAGGA 240				181 AACACATTATGGAATTAATACCTTGTAGCCACATTATAGACGGGAGGA 240				241 AATCACACG 249				241 AATCACACG 249				241 AATCACATG 249			
query	Match	Score	Length																																																																	
96.8%	DB 1;	4149;																																																																		
98.0%	Pred. No.	1.4e-31;																																																																		
244; Conservative	0;	Mismatches	0;																																																																	
	5;	Indels	0;																																																																	
		Gaps	0;																																																																	
1 GGGGTACGCCAGATTCTGGAAAAACCGCTAGAAAATCAGAGTAAATAATCG 60																																																																				
1 GGGGTACGCCAGATTCTGGAAAAACCGCTAGAAAATCAGAGTAAATAATCG 60																																																																				
61 AAATATATCAATTCTTGACACATACTACAGTGTCTTTTAACTATACAA 120																																																																				
61 AAATATATCAATTCTTGACACATACTACAGTGTCTTTTAACTATACAA 120																																																																				
121 CACAAATAATTGTTGTTGATTAGGTGTTATAATAATAACTCTAGGGTTAACGC 180																																																																				
121 CACAAATAATTGTTGTTGATTAGGTGTTATAATAATAACTCTAGGGTTAACGC 180																																																																				
181 AACACATTATGGAATTAATACCTTGTAGCCACATTATAGACGGGAGGA 240																																																																				
181 AACACATTATGGAATTAATACCTTGTAGCCACATTATAGACGGGAGGA 240																																																																				
241 AATCACACG 249																																																																				
241 AATCACACG 249																																																																				
241 AATCACATG 249																																																																				
RESULT 4																																																																				
PGI2XXX	9672 bp DNA linear	BCT 07-JUL-2002																																																																		
Bacillus thuringiensis plasmid pGI2 with transposon Tn4340.																																																																				
X1348.1	X1348.1	X1348.1																																																																		
GI:311732	GI:311732	GI:311732																																																																		
plasmid; pGI2; recombinase; resolvase; transposase;	plasmid; pGI2; recombinase; resolvase; transposase;	plasmid; pGI2; recombinase; resolvase; transposase;																																																																		
transposon; unidentified reading frame.	transposon; unidentified reading frame.	transposon; unidentified reading frame.																																																																		
Bacillus thuringiensis	Bacillus thuringiensis	Bacillus thuringiensis																																																																		
Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus cereus group	Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus cereus group	Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus cereus group																																																																		
1 (bases 1 to 999)	1 (bases 1 to 999)	1 (bases 1 to 999)																																																																		
Mahillon, J. and Seurinck, J.	Mahillon, J. and Seurinck, J.	Mahillon, J. and Seurinck, J.																																																																		
Plasmid nucleotide sequence of pGI2, a <i>Bacillus thuringiensis</i> plasmid containing Tn4340	Plasmid nucleotide sequence of pGI2, a <i>Bacillus thuringiensis</i> plasmid containing Tn4340	Plasmid nucleotide sequence of pGI2, a <i>Bacillus thuringiensis</i> plasmid containing Tn4340																																																																		
Nucleic Acids Res. 16 (24), 11827-11828 (1988)	Nucleic Acids Res. 16 (24), 11827-11828 (1988)	Nucleic Acids Res. 16 (24), 11827-11828 (1988)																																																																		
3211732	3211732	3211732																																																																		
2	2	2																																																																		
REFERENCE	REFERENCE	REFERENCE																																																																		
AUTHORS	AUTHORS	AUTHORS																																																																		
TITLE	TITLE	TITLE																																																																		
JOURNAL	JOURNAL	JOURNAL																																																																		
REMARK	REMARK	REMARK																																																																		
REFERENCE	REFERENCE	REFERENCE																																																																		
AUTHORS	AUTHORS	AUTHORS																																																																		
TITLE	TITLE	TITLE																																																																		
JOURNAL	JOURNAL	JOURNAL																																																																		
REMARK	REMARK	REMARK																																																																		
ENVIRONMENT	ENVIRONMENT	ENVIRONMENT																																																																		
FACTORES	FACTORES	FACTORES																																																																		
SOURCE	SOURCE	SOURCE																																																																		

| Hoflack, L. Direct Submission |
| Submitted (04-Mar-1998) Hoflack L., Plant Genetics Systems, J Plateaustraat 22, B-3000 Gent, Belgium |
| revised by [3] |
| (bases 1 to 9672) |
| On Jun 2, 1998 this sequence version replaced gi:40316. |
| Location/Qualifiers |
| 1/9672 |
| /organism=Bacillus thuringiensis |
| /organism=Bacillus thuringiensis |

```

/mol_type="genomic DNA"
/strain="thermogenicus HI-1."
/db_xref="TAXON:1438"
/plasmid="PGI2"
/organism="Trichomonas vaginalis"
/transposon="Tru430n"
433..451
/note="direct repeat 1"
493..497
/note="inverted repeat A"
498..535
/translation="MDVAQFSSYLAQBNP
KLYRNTTISYLIVKVNQMLNANSINIKRI
CPTVYASPTQIVELDPLQFQSYLSDLEDNKKR
TGCBLTSKSGKCPBVLJLNSKVLSAKDV
VNRKPSISVNPHTPHQLRHFFCTNALEKQ
LNKRMELLH"
1617..1619
/codon_start=1
/translate=1
/trans_start=1
/trans_end=1
/product="Tnp1 ribelvase"
/protein_id="CAA31332_1"
/db_xref="GI:433187"
/db_xref="GOA:PI00010"
/db_xref="SWISS-PROT:PI0020"
/translation="MDVAQFSSYLAQBNP
KLYRNTTISYLIVKVNQMLNANSINIKRI
CPTVYASPTQIVELDPLQFQSYLSDLEDNKKR
TGCBLTSKSGKCPBVLJLNSKVLSAKDV
VNRKPSISVNPHTPHQLRHFFCTNALEKQ
LNKRMELLH"
1617..1619
/codon_start=1
/translate=1
/product="Tnp1 transposase"
/protein_id="CAA31333_1"
/db_xref="GI:433187"
/db_xref="GOA:PI0011"
/db_xref="SWISS-PROT:PI0021"
/translation="MGVKQILSEARQIL
RGYNRLGFLALRVLQPRPLSITLIDKII P
ENLGEFRTTEYQEVQESSEKETTLEOFVQO
YILEDIVVQPAQOKVTKISLTDGFLQVQ
SPSFSLVFLDQFQPKGTTIDTGTKTNT
SPSFLIBITODLIDIAEHDRLMMNQMSV
TLJEEAKTQDAALEDEHDLRMMNQMSV
PTIJERAKTQDAALEDEHDLRMMNQMSV
PTIJERSLHFATKSPCPVQALDTIHLNL
NKRYTHTLAALDTRNHRHRSGLFPGES
LKADBYTDTRNLRALHTRLSKNSZTLE
HSMPLRKLTDLQVLLVASTGPMQHDQPHQTHA
MAEATGQISYROMANASQEMYDDAMYRA
TDIAVRLHADSNPMPHGIGKAGTLYRVS
TDIURKIEHPLHDTAGTQDFQPHLTLGFRS
KGKCNVNUKLKENYETIRRLAYSVQTCGFS
MELPTLDVSYNTAVPVRVQGNGEANAA
IINAIASWVTPMEKAVELKARGEFRE
QHNTQPRIPVTFVY
4609..4616
/note="inverted repeat A"
4647..4651
/note="direct repeat 1"
4833..4839
/note="unnamed protein produc
/codon_start=1
/translate=1
/protein_id="CAA31336_1"
/db_xref="GI:3171733_1"
/db_xref="GOA:PI0022"
/db_xref="SWISS-PROT:PI0022"
/translation="MTNTNDKFKEVQAR
LSKATGSKBKHIFPGRKPSPKVQKAPTO
KSCNHSKBDHIFPGRKPSPKVQKAPTO
ARTALPJPNTIYSERDVEVTTKLF
603..6849
/note="unnamed protein produc
/codon_start=1
/translate=1
/protein_id="CAA31337_1"
/db_xref="GI:3171734_1"
/db_xref="GOA:PI0023"
/db_xref="SWISS-PROT:PI0023"

```

Query Match	Score 96.8†	Score 241; DB 1; Length 9672;	
Best Local Similarity	98.0‡	Pred. No. 1.2e-31;	
Matches 244;	Conservative 0;	Mismatches 5;	Indels 0;
Dy	1 GGGTACCGCAGATTCGAAAAAACACGCTAAGAAATTCAAGTTAAAAATCG 60		
Ddb	498 GGGTACGCCAGATTTCGAAAATAACCGCTTAAATCGATTCGTTAAAAATCG 557		
Qy	61 AAAATAATCATATTCTTGACACATACATGTCTTTTATCAAATAATACAA 120		
Ddb	558 AAAATAATCATATTCCAAAGCACATACATGTCTTTTATCAAATAATACAA 617		
Dy	121 CACATTAATATCTGTGTATAGGTGTATAATAATAATACTAGGGTTAACCC 180		
Ddb	618 CACATTAATATCTGTGTATAGGTGTATAATAATAATACTAGGGTTAACCC 677		
Qy	181 AACACATTATCGTATAATAACTTTAGGCAACCATTTATAGCGCGAGGA 240		
Ddb	678 AACACATTATCGTATAATAACTTTAGGCAACCATTTATAGCGCGAGGA 737		
Qy	241 ATTCACATG 249		
Ddb	738 ATTCACATG 746		
RESULT 5			
	AX6711523	118 bp	DNA
DEFINITION	Sequence 2 from Patent WO2003004652.		
VERSION	AX6711523		
KEYWORDS	Bacillus thuringiensis		
ORGANISM	Bacillus thuringiensis		
CERES GROUP	Bacillales; Bacillaceae; Bacillus; Bacillus		
REFERENCE	1 Stewart, F.A., Zhang, Y. and Halle, B.		
AUTHORS	Zhang, Y. and Halle, B.		